Waxman/Hatch extensions may be added to 20-year GATT term for most patents -- federal appeals court.
WAXMAN/HATCH EXTENSIONS MAY BE ADDED TO 20-YEAR GATT PATENT TERM if the original 17-year term of the patent was in force at the time the Uruguay Rounds Agreement Act took effect June 8, 1995, under a ruling by the D.C. federal appeals court. Chief Judge Glenn Archer, Senior Circuit Judge Helen Nies and Circuit Judge Paul Michel decided the consolidated cases of Merck, Schering-Plough, Bracco, Roche and Organon v. FDA, the Patent & Trademark Office and the Generic Pharmaceutical Industry Association April 4. The court issued a split ruling: patents that were in force when the URAA took effect by virtue of Waxman/Hatch extensions will not be able to add the Waxman/Hatch time to a 20-year term.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth